CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 73 filers reported holding CONCERT PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $865,488 | -12.8% | 148,200 | 0.0% | 0.02% | -18.5% |
| Q3 2022 | $993,000 | +59.1% | 148,200 | 0.0% | 0.03% | +92.9% |
| Q2 2022 | $624,000 | +98.7% | 148,200 | +59.0% | 0.01% | +133.3% |
| Q1 2022 | $314,000 | -32.8% | 93,200 | -37.1% | 0.01% | -33.3% |
| Q4 2021 | $467,000 | -3.7% | 148,200 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $485,000 | +1.7% | 148,200 | +31.0% | 0.01% | 0.0% |
| Q2 2021 | $477,000 | -6.5% | 113,100 | +96.0% | 0.01% | -25.0% |
| Q1 2020 | $510,000 | -33.2% | 57,700 | -30.2% | 0.01% | +20.0% |
| Q4 2019 | $763,000 | -10.6% | 82,700 | -43.0% | 0.01% | -16.7% |
| Q3 2019 | $853,000 | -51.0% | 145,100 | 0.0% | 0.01% | -45.5% |
| Q2 2019 | $1,741,000 | -26.3% | 145,100 | -25.8% | 0.02% | -24.1% |
| Q1 2019 | $2,361,000 | -13.0% | 195,600 | -9.6% | 0.03% | -19.4% |
| Q4 2018 | $2,715,000 | -15.4% | 216,300 | 0.0% | 0.04% | +16.1% |
| Q3 2018 | $3,210,000 | -11.8% | 216,300 | 0.0% | 0.03% | -16.2% |
| Q2 2018 | $3,640,000 | -3.7% | 216,300 | +31.1% | 0.04% | -9.8% |
| Q1 2018 | $3,779,000 | -12.6% | 165,000 | -1.3% | 0.04% | -12.8% |
| Q4 2017 | $4,323,000 | +596.1% | 167,100 | +296.9% | 0.05% | +571.4% |
| Q3 2017 | $621,000 | +5.8% | 42,100 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $587,000 | -51.0% | 42,100 | -40.1% | 0.01% | -53.3% |
| Q1 2017 | $1,199,000 | +313.4% | 70,300 | +149.3% | 0.02% | +275.0% |
| Q4 2016 | $290,000 | +1.8% | 28,200 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $285,000 | -10.1% | 28,200 | 0.0% | 0.00% | -20.0% |
| Q2 2016 | $317,000 | -46.6% | 28,200 | -35.2% | 0.01% | -50.0% |
| Q1 2016 | $594,000 | -28.3% | 43,500 | -0.5% | 0.01% | -33.3% |
| Q4 2015 | $829,000 | +1.5% | 43,700 | +0.5% | 0.02% | -11.8% |
| Q3 2015 | $817,000 | +26.1% | 43,500 | 0.0% | 0.02% | +30.8% |
| Q2 2015 | $648,000 | -1.7% | 43,500 | 0.0% | 0.01% | -7.1% |
| Q1 2015 | $659,000 | +13.8% | 43,500 | 0.0% | 0.01% | +7.7% |
| Q4 2014 | $579,000 | +240.6% | 43,500 | +222.2% | 0.01% | +225.0% |
| Q3 2014 | $170,000 | +25.0% | 13,500 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $136,000 | – | 13,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |